The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | A short discussion of the unmet needs of CLL patients
Davide Rossi, MD, PhD from University of Eastern Piedmont, Vercelli, Italy discusses the unmet needs of chronic lymphocytic leukemia (CLL) patients. There are issues related the treatment of elderly patients and ultra-high risk patients with mutations of the TP53 gene. Furthermore, the issue of affordability of these novel agents must be tackled. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
